Subcutaneous (Sub-Q) or Intramuscular (IM): Common for targeting muscle or tendon injuries directly
Tumor risk via p53 pathway interference Mitigate risk by: Careful patient selection: exclude patients with pre-existing active malignancy or high tumour risk (e.g., known p53 mutations, familial cancer syndromes)
Wu, J.C., et al., Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition
Wound Healing BPC-157, a penta-decapeptide composed of 15 amino acids, has demonstrated remarkable efficacy in accelerating the process of wound healing
Our team will work closely with you to monitor your progress, adjust your treatment plan as needed, and address any side effects or concerns
Combine oral and topical whitening products to boost results, but ensure product quality and be mindful of possible drug interactions